Centessa Pharmaceuticals Statistics
Share Statistics
Centessa Pharmaceuticals has 131.66M shares outstanding. The number of shares has increased by 15.93% in one year.
| Shares Outstanding | 131.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 12.63% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 90.14M |
| Failed to Deliver (FTD) Shares | 5.02K |
| FTD / Avg. Volume | 0.9% |
Short Selling Information
The latest short interest is 2.15M, so 1.77% of the outstanding shares have been sold short.
| Short Interest | 2.15M |
| Short % of Shares Out | 1.77% |
| Short % of Float | 2.62% |
| Short Ratio (days to cover) | 6.28 |
Valuation Ratios
The PE ratio is -5.07 and the forward PE ratio is -9.94.
| PE Ratio | -5.07 |
| Forward PE | -9.94 |
| PS Ratio | 111.71 |
| Forward PS | 8099.8 |
| PB Ratio | 3.24 |
| P/FCF Ratio | -4.77 |
| PEG Ratio | n/a |
Enterprise Valuation
Centessa Pharmaceuticals has an Enterprise Value (EV) of 722.13M.
| EV / Earnings | -4.78 |
| EV / Sales | 105.37 |
| EV / EBITDA | -4.35 |
| EV / EBIT | -4.22 |
| EV / FCF | -4.5 |
Financial Position
The company has a current ratio of 8, with a Debt / Equity ratio of 0.32.
| Current Ratio | 8 |
| Quick Ratio | 8 |
| Debt / Equity | 0.32 |
| Total Debt / Capitalization | 24.27 |
| Cash Flow / Debt | -2.12 |
| Interest Coverage | -17.29 |
Financial Efficiency
Return on equity (ROE) is -0.64% and return on capital (ROIC) is -45.79%.
| Return on Equity (ROE) | -0.64% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -45.79% |
| Revenue Per Employee | 90.17K |
| Profits Per Employee | -1.99M |
| Employee Count | 76 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -25.06M |
| Effective Tax Rate | 0.14 |
Stock Price Statistics
The stock price has increased by 133.19% in the last 52 weeks. The beta is 1.48, so Centessa Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.48 |
| 52-Week Price Change | 133.19% |
| 50-Day Moving Average | 16.46 |
| 200-Day Moving Average | 12.35 |
| Relative Strength Index (RSI) | 48.72 |
| Average Volume (20 Days) | 555.10K |
Income Statement
In the last 12 months, Centessa Pharmaceuticals had revenue of $6.85M and earned -$151.09M in profits. Earnings per share was $-1.57.
| Revenue | 6.85M |
| Gross Profit | 6.85M |
| Operating Income | -171.28M |
| Net Income | -151.09M |
| EBITDA | -166.07M |
| EBIT | -171.28M |
| Earnings Per Share (EPS) | -1.57 |
Balance Sheet
The company has $128.03M in cash and $84.59M in debt, giving a net cash position of $43.44M.
| Cash & Cash Equivalents | 128.03M |
| Total Debt | 84.59M |
| Net Cash | 43.44M |
| Retained Earnings | -752.95M |
| Total Assets | 609.72M |
| Working Capital | 541.96M |
Cash Flow
In the last 12 months, operating cash flow was -$160.34M and capital expenditures -$169.00K, giving a free cash flow of -$160.51M.
| Operating Cash Flow | -160.34M |
| Capital Expenditures | -169.00K |
| Free Cash Flow | -160.51M |
| FCF Per Share | -1.67 |
Margins
Gross margin is 100%, with operating and profit margins of -2.50K% and -2.20K%.
| Gross Margin | 100% |
| Operating Margin | -2.50K% |
| Pretax Margin | -2.57K% |
| Profit Margin | -2.20K% |
| EBITDA Margin | -2.42K% |
| EBIT Margin | -2.50K% |
| FCF Margin | -2.34K% |
Dividends & Yields
CNTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.47% |
| FCF Yield | -7.35% |
Analyst Forecast
The average price target for CNTA is $27, which is 62.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $27 |
| Price Target Difference | 62.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 10.27 |
| Piotroski F-Score | 3 |